# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-02-03
**æ›´æ–°æ—¶é—´**: 2026-02-04 04:10
**æ–°é—»æ•°é‡**: 105

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºé‡ç£…è¯ç‰©ç ”å‘è¿›å±•ä¸ç›‘ç®¡å®¡æ‰¹ã€‚è¯ºå’Œè¯ºå¾·æ–°ä¸€ä»£ä»£è°¢è¯ç‰©CagriSemaåœ¨ç³–å°¿ç—…è¯•éªŒä¸­è¡¨ç°ä¼˜äºå¸ç¾æ ¼é²è‚½ï¼Œæˆä¸ºè‚¥èƒ–ç—‡/ç³–å°¿ç—…é¢†åŸŸçš„é‡è¦çªç ´ï¼›FDAå¯¹CAR-Tç–—æ³•ç”¨äºè‡ªèº«å…ç–«æ€§ç–¾ç—…å±•ç°å‡ºå®¡æ…æ”¯æŒæ€åº¦ï¼ŒåŒæ—¶é˜¿æ–¯åˆ©åº·çš®ä¸‹æ³¨å°„ç‰ˆç‹¼ç–®è¯ç‰©Saphneloé­FDAæ‹’ç»ï¼Œå‡¸æ˜¾ç›‘ç®¡å¤æ‚æ€§ã€‚æ­¤å¤–ï¼Œç¤¼æ¥å®£å¸ƒ35äº¿ç¾å…ƒæ–°å·¥å‚æŠ•èµ„ï¼Œå°åº¦æ”¿åºœæŠ•å…¥11äº¿ç¾å…ƒæ¨åŠ¨ç”Ÿç‰©åˆ¶å‰‚å‘å±•ï¼Œæ˜¾ç¤ºå…¨çƒäº§èƒ½å¸ƒå±€ä¸äº§ä¸šå‡çº§è¶‹åŠ¿ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**9. New CagriSema data show improvement over semaglutide** â­â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - è¯ºå’Œè¯ºå¾·æ–°ä¸€ä»£ä»£è°¢è¯ç‰©CagriSemaåœ¨é™ç³–å‡é‡æ–¹é¢ä¼˜äºé‡ç£…è¯ç‰©å¸ç¾æ ¼é²è‚½ï¼Œå¯èƒ½é‡å¡‘è‚¥èƒ–ç—‡/ç³–å°¿ç—…æ²»ç–—æ ¼å±€

**1. FDA signals tailored approach to 'carefully shepherd' CAR-T therapy for autoimmune diseases** â­â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAé¦–æ¬¡æ˜ç¡®æ”¯æŒCAR-Tç–—æ³•ç”¨äºè‡ªèº«å…ç–«æ€§ç–¾ç—…ï¼Œå¼€è¾Ÿäº†ç»†èƒæ²»ç–—æ–°åº”ç”¨é¢†åŸŸ

**19. Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in Pa.** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - ç¤¼æ¥æŠ•èµ„35äº¿ç¾å…ƒå»ºè®¾æ–°å·¥å‚ï¼Œå®Œæˆå…¶ç¾å›½åˆ¶é€ æ‰©å¼ è®¡åˆ’ï¼Œåº”å¯¹GLP-1è¯ç‰©éœ€æ±‚æ¿€å¢

**14. India will invest $1.1B to boost development of biologics, biosimilars** â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - å°åº¦æ”¿åºœæŠ•å…¥11äº¿ç¾å…ƒæ¨åŠ¨ç”Ÿç‰©åˆ¶å‰‚å‘å±•ï¼Œæ ‡å¿—è¯¥å›½ä»ä»¿åˆ¶è¯å‘ç”Ÿç‰©åˆ¶è¯çš„æˆ˜ç•¥è½¬å‹

**15. FDA rejects AZ's subQ Saphnelo, but company expects quick turnaround for new approval decision** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - é˜¿æ–¯åˆ©åº·çš®ä¸‹æ³¨å°„ç‰ˆç‹¼ç–®è¯ç‰©é­FDAæ‹’ç»ï¼Œä½†å…¬å¸é¢„è®¡å¿«é€Ÿè§£å†³ï¼Œå½±å“é‡è¦äº§å“çº¿æ‰©å±•

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): è¯ºå’Œè¯ºå¾·CagriSemaåœ¨ç³–å°¿ç—…è¯•éªŒä¸­æ˜¾ç¤ºä¼˜äºå¸ç¾æ ¼é²è‚½çš„ç–—æ•ˆï¼›å®‰è¿›æ”¾å¼ƒæ¹¿ç–¹è¯ç‰©å¼€å‘ï¼›ä¸­å›½åŸºå› ç¼–è¾‘åˆåˆ›å…¬å¸AccurEditèèµ„7500ä¸‡ç¾å…ƒæ¨è¿›CRISPRç–—æ³•ï¼›Ultragenyxå…¬å¸ƒåŸºå› ç–—æ³•æ–°æ•°æ®æ”¯æŒé‡æ–°æäº¤ç”³è¯·ï¼›è¾‰ç‘æœˆåº¦GLP-1è¯ç‰©æ˜¾ç¤ºå‡é‡æ•ˆæœã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): CagriSemaåœ¨2å‹ç³–å°¿ç—…æ‚£è€…çš„IIIæœŸè¯•éªŒä¸­è¾¾åˆ°ä¸»è¦ç»ˆç‚¹ï¼›Argo Biopharmaçš„siRNAç–—æ³•BWâ€‘20829å¯åŠ¨IIbæœŸè¯•éªŒï¼›Kyowa Kirinåœ¨æ¹¿ç–¹è¯ç‰©IIIæœŸè¯•éªŒä¸­æŠ«éœ²å‰¯ä½œç”¨äº‹ä»¶ï¼›En Carta Diagnosticsçš„è±å§†ç—…æ£€æµ‹è®¾å¤‡è·FDAçªç ´æ€§è®¾å¤‡è®¤å®šã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

é‡ç‚¹å…³æ³¨FDAå¯¹CAR-Tç”¨äºè‡ªèº«å…ç–«æ€§ç–¾ç—…çš„å…·ä½“ç›‘ç®¡æ¡†æ¶ç»†èŠ‚ï¼›é˜¿æ–¯åˆ©åº·å¦‚ä½•å¿«é€Ÿè§£å†³Saphneloçš®ä¸‹æ³¨å°„ç‰ˆçš„å®¡æ‰¹é—®é¢˜ï¼›è¯ºå’Œè¯ºå¾·CagriSemaä¸ç¤¼æ¥Zepboundçš„å¸‚åœºç«äº‰æ€åŠ¿æ¼”å˜ï¼›å®‰è¿›Tavneosæ•°æ®å®Œæ•´æ€§å®¡æŸ¥çš„æœ€ç»ˆç»“æœåŠå…¶å¸‚åœºå½±å“ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 43 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ FDA signals tailored approach to â€˜carefully shepherdâ€™ CAR-T therapy for autoimmune diseases

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 11:17
- **é‡è¦æ€§**: â­â­â­â­

> As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDAâ€™s Vinay Prasad, M.D., and colleagues have signaled a willingness to support the development of these novel cell therapies with a flexible regulatory approach.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/fda-signals-tailored-approach-carefully-shepherd-car-t-therapy-autoimmune-diseases)

---

### ğŸ‡ºğŸ‡¸ CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 11:35
- **é‡è¦æ€§**: â­â­â­â­

> Sanofi, Novo Nordisk, UCB and others received positive opinions from Europe's Committee for Medicinal Products for Human Use, while Amgen's approved Tavneos is up for a re-review due to data integrity concerns.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/europes-chmp-thumbs-novos-semaglutide-mash-sanofis-rezurock-and-more-while-amgens-tavneos)

---

### ğŸ‡ºğŸ‡¸ CDMO Vetter maps out expansion in Germany with â‚¬480M for new plant

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 17:26
- **é‡è¦æ€§**: â­â­â­

> The German CDMO devoted 480 million euros ($574.3 million) to the first construction phase for a new plant in Saarlouis, Germany, which is expected to be operational by 2031.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/german-cdmo-vetter-takes-global-expansion-spree-its-home-country-eu480m-investment)

---

### ğŸ‡ºğŸ‡¸ India will invest $1.1B to boost development of biologics, biosimilars

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 14:10
- **é‡è¦æ€§**: â­â­

> Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion) over the next five years to increase research and production of biologics and biosimilars

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/india-will-invest-11b-boost-development-biologics-biosimilars)

---

### ğŸ‡ºğŸ‡¸ FDA rejects AZ's subQ Saphnelo, but company expects quick turnaround for new approval decision

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 09:01
- **é‡è¦æ€§**: â­â­

> AstraZeneca will have to negotiate what appears to be a minor speed bump in order to gain clearance in the U.S. for its subcutaneous version of lupus treatment Saphnelo. The FDA has rejected AZ's application that would allow patients to self-administer the monoclonal antibody in a prefilled pen. The advancement would give patients a convenient alternative to traveling to a doctor's office for infusions every four weeks.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo)

---

### ğŸ‡ºğŸ‡¸ With FDA rejections, Aquestive's shares go up, while Pharming's go down

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 11:15
- **é‡è¦æ€§**: â­â­

> The FDA issued complete response letters to Aquestive Therapeutics and Pharming in recent days, resulting in vastly different reactions from the market.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-rejections-aquestives-shares-go-while-pharmings-go-down)

---

### ğŸ‡ºğŸ‡¸ FDA emphasizes drug ingredients, production pledges as it debuts PreCheck manufacturing program

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 10:02
- **é‡è¦æ€§**: â­â­

> Amid an outpouring of industry investments in U.S. drug production, the FDA has launched a new program designed to reduce the complexities involved in setting up domestic manufacturing plants.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-emphasizes-drug-ingredients-production-pledges-it-debuts-precheck-manufacturing-program)

---

### ğŸ‡ºğŸ‡¸ A sales turnaround for Regeneron's Eylea franchise will have to wait at least another quarter

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 11:15
- **é‡è¦æ€§**: â­â­

> For the last several quarters, declining sales of Regeneron's eye disease treatment Eylea have exceeded increasing sales of the drug's new version, Eylea HD, leading to a steady decline in overall U.S. sales for the Eylea franchise. The company said Friday the trend will continue in the first quarter of this year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/turnaround-regenerons-eylea-will-have-wait-least-another-quarter)

---

### ğŸ‡ºğŸ‡¸ Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in Pa.

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 09:19
- **é‡è¦æ€§**: â­â­

> On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvaniaâ€™s Lehigh Valley, rounding out the quartet of plants it promised during its â€œLilly in Americaâ€ investment announcement last year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/lilly-rounds-out-quartet-new-us-plants-35b-injectables-and-device-facility-pa)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Pfizer obesity pill, Floridaâ€™s failed drug importation plan, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 14:28
- **é‡è¦æ€§**: â­â­

> Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks in a mid-stage study

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about obesity drug sales, Indiaâ€™s biopharma research push, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 14:30
- **é‡è¦æ€§**: â­â­

> The long-held expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/02/obesity-lilly-novo-sanofi-india-pfizer-fda/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Lilly, Repertoire strike $2 billion autoimmune alliance

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:03
- **é‡è¦æ€§**: â­â­

> And other biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/biotech-news-lilly-repertoire-strike-autoimmune-alliance/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about AstraZeneca investing in China, an abandoned overdose antidote, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 14:23
- **é‡è¦æ€§**: â­â­

> AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/29/astrazeneca-hologen-kickbacks-overdose-lilly-china/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ BMS, J&amp;J factor in HCP education on clot-busting mechanism before milvexian data drop

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 09:42
- **é‡è¦æ€§**: â­

> Bristol Myers Squibb and Johnson &amp; Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/bms-jj-factor-physician-education-clot-busting-mechanism-x-factor-readouts)

---

### ğŸ‡ºğŸ‡¸ Fierce Pharma Asiaâ€”AZ's $15B China investment; Boehringer, Simcere's IBD deal; Daiichi's ADC growth push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 15:08
- **é‡è¦æ€§**: â­

> AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the country. Boehringer Ingelheim secured a preclinical inflammatory bowel disease bispecific from Simcere. Daiichi Sankyo's U.S. chief talked about the successâ€”and challengesâ€”the company is seeing with Enhertu and Datroway. And more.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/az-15b-china-investment-boehringer-simcere-ibd-deal-daiichi-adc-growth-push)

---

### ğŸ‡ºğŸ‡¸ HHS launches $100M antiviral prize to develop broad-spectrum therapies

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 14:39

> While the Trump administration may be pivoting away from certain vaccinations, it is pushing for the development of antiviral therapies via the launch of a $100 million antiviral therapy development competition.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/hhs-launches-100-million-antiviral-prize-develop-broad-spectrum-therapies)

---

### ğŸ‡ºğŸ‡¸ Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the doors

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 13:39

> Novo Nordisk turned in sales and profit growth in 2025 amid an intense obesity market rivalry with Eli Lilly. But investor optimism came to a sudden halt Tuesday as the company warned of significant sales and earnings declines in 2026.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novo-shares-plummet-sales-profit-warning-26)

---

### ğŸ‡ºğŸ‡¸ Charles River to close cell therapy CDMO site, lay off 20 staffers

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 12:02

> Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will cost the company 20 jobs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/cro/charles-river-close-cell-therapy-cdmo-site-lay-20-staffers)

---

### ğŸ‡ºğŸ‡¸ Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 11:43

> As top-selling Keytruda inches closer to its 2028 patent cliff, Merck's confidence in sustainable growth for the future is "as high as it's ever been," CEO Robert Davis said on the company's full-year 2025 earnings call.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/merck-confident-post-keytruda-future-70b-opportunity-next-decade-growth-drivers)

---

### ğŸ‡ºğŸ‡¸ Sanofi sanctioned by PMCPA over CEO's 'bold claims' about Pfizer RSV vaccine

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 05:34

> A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. governmentâ€™s vaccine program by making â€œbold claimsâ€ about a procurement choice.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/sanofi-sanctioned-over-ceos-bold-claims-about-pfizer-vaccine)

---

### ğŸ‡ºğŸ‡¸ AbbVie has â€˜Love in Mindâ€™ with new migraine educational campaign

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 12:11

> With Valentineâ€™s Day coming up, AbbVie has love on the brain. Ahead of the holiday, the Big Pharma has unveiled a new campaign focusing on how migraines can impact romantic relationships.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/abbvie-has-love-mind-new-migraine-educational-campaign)

---

### ğŸ‡ºğŸ‡¸ Thermo Fisher trims Massachusetts headcount with Franklin site closure

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 11:06

> Thermo Fisher is continuing its recent layoff spree with a fresh round of cuts tied to a site itâ€™s shuttering in Franklin, Massachusetts, which currently employs about 200 people.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/thermo-fisher-trims-massachusetts-headcount-franklin-site-closure)

---

### ğŸ‡ºğŸ‡¸ Why human expertise still matters in AI-driven med comms

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 16:32

> RTI Health Solutions experts explain how AI can help medical communications without replacing rigor, judgment or trust.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/sponsored/why-human-expertise-still-matters-ai-driven-med-comms)

---

### ğŸ‡ºğŸ‡¸ Trump administration officials are at loggerheads over future of COVID vaccines: Axios

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 06:55

> Some officials in the Trump administration are at odds with others who are helping shape vaccine policy over whether to remove COVID vaccines from the U.S. market, according to a report from Axios.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trump-administration-officials-are-loggerheads-over-covid-vaccines-report)

---

### ğŸ‡ºğŸ‡¸ Quince Therapeutics on the brink as steroid-in-blood-cell fails in rare genetic disease

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 09:57

> Quince Therapeuticsâ€™ novel method of delivering steroids in a patientâ€™s own red blood cells turned out to be a bust in ataxia-telangiectasia, a rare inherited disorder, with the company now planning to â€œpreserve cash and explore available options.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/quince-therapeutics-teeters-edge-steroid-blood-cell-fails-rare-genetic-disease)

---

### ğŸ‡ºğŸ‡¸ Biopharma's rebound keeping pace so far

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 15:56

> This week on "The Top Line," we explore biopharma's rebound, dealmaking momentum and what's cutting through the noise in 2026.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/biopharmas-rebound-keeping-pace-so-far)

---

### ğŸ‡ºğŸ‡¸ Novo gets Chamber of Commerce backing in bid to bring IRA challenge to Supreme Court

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 14:36

> On Wednesday, the U.S. Chamber of Commerce filed an amicus brief calling on the Supreme Court to review a lower court decision that previously rejected Novo Nordisk's challenge of drug pricing provisions in the Inflation Reduction Act. As with other challenges to the IRA, the Chamber argued that the negotiations baked into the law are â€œillusory."

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novo-gets-chamber-commerce-backing-bid-bring-ira-challenge-supreme-court)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 17:38

> Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer unveils data on Metsera drug

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 14:41

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer moves forward with its hopes for a monthly obesity drug

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 12:22

> Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing increasingly competitive.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/pfizer-obesity-weight-loss-drug-monthly-metsera-pf3944-met097/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: As U.S. officials move to reduce animal testing in research, focus may shift to restrictions on imports

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 09:30

> The Trump administration is seeking to reduce animal testing in research. Some activists are pushing the administration to suspend primate imports for research purposes entirely.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/03/animal-lab-research-imports-kennedy/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: A play takes on Novoâ€™s myth and money

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 14:51

> And more biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/biotech-news-golden-calf-novo-nordisk-play-theater/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Sanofi is reprimanded by a U.K. trade group for misleading claims about a Pfizer vaccine

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 13:47

> Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and disparaging a rival product from Pfizer.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/02/pfizer-sanofi-rsv-vaccine-uk/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimerâ€™s

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 09:30

> Why Bristol Myers Squibb is banking on a decades-old drug to help secure its future.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: As its immunology work draws attention, Sanofi also pushes forward in rare disease

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 06:00

> An experimental Sanofi drug helped improve the neurological problems seen with a rare disease, as the company plans to seek approval.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/sanofi-venglustat-gaucher-rare-disease-neurological-symptoms/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 17:06

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/30/pharma-biotech-jobs-abbvie-merck-biontech-moderna-takeda-novo/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: New rule would force PBMs to disclose drug rebates and other fees

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 15:48

> The proposal would mark a significant change for the secretive PBM industry, which often shields crucial data from its clients.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/30/pbm-drug-rebate-transparency-proposed-rule-department-of-labor/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: AstraZeneca looks to China for obesity drug candidates

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 14:36

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/30/biotech-news-astrazeneca-china-obesity-drug-candidates/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about TrumpRx questions, drugmakers lowering some prices, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 14:35

> Three U.S. senators sent a letter to the HHS Office of Inspector General raising questions about TrumpRx â€” whose structure has yet to be detailed

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/30/trump-telehealth-obesity-pbm-insulin-astrazeneca-china/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: States are the next vaccine battleground

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 17:07

> This is the web edition of STAT's D.C. Diagnosis newsletter.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/state-vaccine-mandates-health-care-ice-minnesota-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Oz, other officials meet with key senators to push Trumpâ€™s ideas for lower drug prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:30

> Trump wants lawmakers to force pharma companies to lower their prices, but it's not clear the GOP is on board.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/mehmet-oz-senate-finance-committee-meeting-most-favored-nations-drug-pricing/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: How Opvee, Indiviorâ€™s powerful overdose antidote, went bust

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 09:30

> Opvee reverses opioid overdose more quickly than Narcan. It also can cause withdrawal symptoms. Harm reduction advocates fought it, and won.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/why-opvee-overdose-antidote-failed-harm-reduction-community-opposition/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Eli Lilly expands work on gene therapies for hearing

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:49

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/28/biotech-news-eli-lillly-expands-gene-therapy-for-hearing/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 12:51
- **é‡è¦æ€§**: â­â­â­â­

> Pfizer took a write-down on one of its recent high-profile acquisitions while reporting a positive readout from another. The pharma giant said on Tuesday it took a $4.4 billion impairment charge related in part to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 12:03
- **é‡è¦æ€§**: â­â­â­â­

> The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/)

---

### ğŸ‡ºğŸ‡¸ First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 20:42
- **é‡è¦æ€§**: â­â­â­â­

> The first 10 drugs that underwent government price negotiations in 2023 were projected to save the government billions of dollars. Now, one month since the new pricing took effect, the extent to which those savings ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/first-10-medicare-negotiated-drug-prices-have-taken-effect-are-seniors-really-saving-money/)

---

### ğŸ‡ºğŸ‡¸ Amgen gives up on its once-prized eczema drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 16:57
- **é‡è¦æ€§**: â­â­â­

> The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/amgen-return-rocatinlimab-kyowa-kirin-atopic-dermatitis-eczma-ox40/810964/)

---

### ğŸ‡ºğŸ‡¸ New CagriSema data show improvement over semaglutide

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 19:16
- **é‡è¦æ€§**: â­â­â­

> Novo Nordiskâ€™s next-gen metabolic drug CagriSema performed better than the blockbuster semaglutide at reducing blood sugar and weight in patients with type 2 diabetes. That was the topline result from the latest Phase 3 readout ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/new-cagrisema-data-show-improvement-over-semaglutide/)

---

### ğŸ‡ºğŸ‡¸ Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPT

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 15:22
- **é‡è¦æ€§**: â­â­â­

> Plus, news on AstraZeneca, Johnson &amp; Johnson, Averin Capital and Chugai: ğŸ§ª Kyowa Kirin discloses side effect for recently regained drug: A patient participating in a Phase 3 trial to treat eczema developed a case ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/kyowa-kirin-reveals-side-effect-in-trial-gsk-was-lone-bidder-for-rapt/)

---

### ğŸ‡ºğŸ‡¸ FDA launches â€˜PreCheckâ€™ program; AstraZeneca, Acadia drugs set back

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-03 15:11
- **é‡è¦æ€§**: â­â­

> The agency&rsquo;s program will be open to pharmaceutical facilities that align with &ldquo;national priorities.&rdquo; Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene therapy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/fda-precheck-astrazeneca-acadia-reject-meiragtx/811092/)

---

### ğŸ‡ºğŸ‡¸ Novo combination obesity shot meets goal in diabetes trial

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 19:00
- **é‡è¦æ€§**: â­â­

> CagriSema&rsquo;s blood sugar and weight reductions exceeded the company&rsquo;s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/novo-cagrisema-diabetes-reimagine-study-results/811115/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca leans into obesity, striking wide-ranging alliance with Chinaâ€™s CSPC

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 12:36
- **é‡è¦æ€§**: â­â­

> The deal, which involves up to eight &ldquo;next-generation&rdquo; weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/astrazeneca-obesity-deal-china-cspc-ai/810942/)

---

### ğŸ‡ºğŸ‡¸ Politicization runs deeper than ever at FDA, risking long-term impacts

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 12:00
- **é‡è¦æ€§**: â­â­

> A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration&rsquo;s political agenda, according to an economist and public policy expert.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/fda-politicization-deeper-than-ever-risking-long-term-impacts/810909/)

---

### ğŸ‡ºğŸ‡¸ FDA seeks withdrawal of Amgen's Tavneos, company says it won't pull drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 00:48
- **é‡è¦æ€§**: â­â­

> Several years of questions about Amgen's rare disease treatment Tavneos have come to a climax after the FDA asked the company to pull the drug from the market, and Amgen said it has no plans ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-seeks-withdrawal-of-amgens-tavneos-company-says-it-wont-pull-drug/)

---

### ğŸ‡ºğŸ‡¸ UKâ€™s health department expected to spend Â£1B in pharma trade deal with US

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 00:01
- **é‡è¦æ€§**: â­â­

> The UK's drug pricing deal with the White House is expected to cost Â£1 billion between 2026 and 2029, according to a letter from the country's science minister. The letter was published Wednesday morning by ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/uks-health-department-expected-to-spend-1b-in-pharma-trade-deal-with-us/)

---

### ğŸ‡ºğŸ‡¸ What's driving health tech M&A

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 16:28
- **é‡è¦æ€§**: â­â­

> The past week saw a flurry of health tech acquisitions (we counted at least five!). Part of the rush of activity is seasonal â€” the end of the year often serves as a ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/whats-driving-health-tech-ma/)

---

### ğŸ‡ºğŸ‡¸ China startup AccurEdit raises $75M for gene editing therapies

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 16:13
- **é‡è¦æ€§**: â­â­

> AccurEdit Therapeutics, a startup based in Suzhou, China, has raised $75 million in Series A funding to advance its growing pipeline of CRISPR-based medicines â€” among the largest rounds on record for a Chinese gene editing ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/)

---

### ğŸ‡ºğŸ‡¸ Ultragenyx unwraps data that may be central to its gene therapy resubmission

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 13:00
- **é‡è¦æ€§**: â­â­

> Ultragenyx outlined new data on Tuesday that it hopes will convince the FDA to approve its recently resubmitted rare disease gene therapy. Among 17 patients with Sanfilippo syndrome type A who received the therapy, cognition ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/ultragenyx-unwraps-data-that-may-be-central-to-its-gene-therapy-resubmission/)

---

### ğŸ‡ºğŸ‡¸ Updated: Do Pfizerâ€™s monthly GLP-1 data justify Metseraâ€™s $10B price tag?

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 12:30
- **é‡è¦æ€§**: â­â­

> Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/)

---

### ğŸ‡ºğŸ‡¸ FDA rejects Aquestive's allergy drug over packaging issues

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 15:17
- **é‡è¦æ€§**: â­â­

> The FDA has delivered a complete response letter to Aquestive Therapeutics for its allergy medication due to issues over the drugâ€™s packaging. The agency declined to approve Aquestiveâ€™s allergy patch called Anaphylm in patients weighing ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-rejects-aquestives-allergy-drug-over-packaging-issues/)

---

### ğŸ‡ºğŸ‡¸ FDA opens submissions for PreCheck program to speed up US factory builds

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 14:46
- **é‡è¦æ€§**: â­â­

> The FDA has started accepting pitches for drugmakers to participate in the agencyâ€™s PreCheck program, a new initiative aimed to speed up the construction of US manufacturing sites. The agency

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-opens-submissions-for-precheck-program-to-speed-up-us-factory-builds/)

---

### ğŸ‡ºğŸ‡¸ Pharmingâ€™s immunodeficiency drug gets CRL for use in younger patients

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 11:52
- **é‡è¦æ€§**: â­â­

> The FDA has issued a complete response letter to Pharming, rejecting its attempt to expand the approval of its drug for a rare form of immunodeficiency into younger patients. Joenja was

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/pharmings-immunodeficiency-drug-gets-crl-for-use-in-younger-patients/)

---

### ğŸ‡ºğŸ‡¸ Pfizer dips on new data for obesity drug acquired in $10B deal

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-03 17:01
- **é‡è¦æ€§**: â­

> A long-acting shot Pfizer got through a buyout of Metsera appeared &ldquo;slightly inferior&rdquo; to Lilly&rsquo;s market-leading Zepbound in a Phase 2 trial, one analyst said.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/pfizer-obesity-metsera-phase-2-results-GLP1-monthly-shot/811201/)

---

### ğŸ‡ºğŸ‡¸ Sanofiâ€™s venglustat succeeds in Phase 3 Gaucher trial but fails separate study in Fabry disease

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 12:12
- **é‡è¦æ€§**: â­

> Sanofiâ€™s investigational drug, with a track record of mixed results in the clinic, has passed a Phase 3 trial in Gaucher disease, but flunked a separate late-stage study in Fabry disease.

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/)

---

### ğŸ‡ºğŸ‡¸ Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 17:12

> The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/sanofi-venglustat-gaucher-fabry-study-results/811113/)

---

### ğŸ‡ºğŸ‡¸ GSK walks away from pioneering Wave RNA editing drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 13:31

> Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/wave-gsk-reacquire-rna-editing-drug-aatd/811067/)

---

### ğŸ‡ºğŸ‡¸ Building a robust in-process testing plan for cell therapy manufacturing success

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 10:00

> The roadmap to reliable inâ€‘process testing for cell therapy success.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/spons/building-a-robust-in-process-testing-plan-for-cell-therapy-manufacturing-su/810800/)

---

### ğŸ‡ºğŸ‡¸ The biopharma industry outlook on 2026: Optimism and tension

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 19:31

> A spike in M&amp;A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/biotech-pharma-trends-outlook-2026/810833/)

---

### ğŸ‡ºğŸ‡¸ Novo expects sales to fall in 2026, triggering selloff

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 20:07

> Novo Nordisk expects its sales to shrink by at least 5% this year, citing negative pricing dynamics, including its deal with the US government. The Danish pharma said in its

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/)

---

### ğŸ‡ºğŸ‡¸ 'Turning around the Titanic': How the incoming PBM reforms will transform CMS

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 19:34

> The Centers for Medicare and Medicaid Services has never played a significant role in regulating pharmacy benefit managers, the middlemen that have historically relied on high drug prices for profits. But the government spending package ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/turning-around-the-titanic-how-the-incoming-pbm-reforms-will-transform-cms/)

---

### ğŸ‡ºğŸ‡¸ Daiichi ends work on an ADC; Layoffs at GSK's R&D unit

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 15:30

> Plus, news about Acadia Pharmaceuticals, Eli Lilly, PepLib Biotech, MeiraGTx, ZipBio, SantÃ© Ventures, Adlai Nortye, NMD Pharma, Eton Pharmaceuticals, vTv Therapeutics and Newsoara: âœ‚ï¸ Daiichi Sankyo culls next-gen ADC: Citing a strategic portfolio review ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/daiichi-ends-work-on-an-adc-layoffs-at-gsks-rd-unit/)

---

### ğŸ‡ºğŸ‡¸ Menlo and a16z back AI scientist startup Phylo

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 12:00

> Within days of defending their PhDs last year, two Stanford University researchers incorporated their own startup, betting they could build a business around their AI system that handles scientific tasks. The Bay Area startup, called ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/menlo-and-a16z-back-ai-scientist-startup-phylo/)

---

### ğŸ‡ºğŸ‡¸ Carbon Health files for bankruptcy, seeking to sell or restructure

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 21:22

> Carbon Health has filed for bankruptcy protection and is seeking to restructure or sell itself, the urgent and primary care startup said Monday. The company voluntarily filed for Chapter 11 in the US Bankruptcy Court ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/carbon-health-files-for-bankruptcy-seeking-to-sell-or-restructure/)

---

### ğŸ‡ºğŸ‡¸ GSK returns rights to Wave's RNA editing program for AATD

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 16:06

> GSK no longer plans to collaborate on a closely-watched RNA editing program from Wave Life Sciences, whose fate could influence the prospects of the emerging field. Wave announced Monday that GSK ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/gsk-returns-rights-to-waves-rna-editing-program-for-aatd/)

---

### ğŸ‡ºğŸ‡¸ Spring Health acquires Alma, expanding insurance reach in virtual mental health

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 15:43

> Spring Health is the latest virtual mental health company to lean into insurance as it acquires competitor Alma. The deal, announced Thursday, would give Spring, which has traditionally focused on providing mental health services as ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/spring-health-acquires-alma-expanding-insurance-reach-in-virtual-mental-health/)

---

### ğŸ‡ºğŸ‡¸ SanegeneBio licenses RNAi candidate to Genentech for $200M upfront

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 14:35

> Genentech will pick up an RNAi candidate from SanegeneBio, a China and US biotech fresh off a $110 million Series B. The Roche unit will pay $200 million upfront for the global ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/sanegenebio-licenses-rnai-candidate-to-genentech-for-200m-upfront/)

---

### ğŸ‡ºğŸ‡¸ European law changes mean drugmakers may have to grapple with generic competition sooner

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 06:00

> European regulators will soon sign in a new raft of laws that could make drugmakers jump through more hoops to delay generic and biosimilar competition. And companies developing rare disease and orphan drugs are likely ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/imminent-european-law-changes-mean-drugmakers-may-have-to-grapple-with-generic-competition-sooner/)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:18
- **é‡è¦æ€§**: â­â­â­â­

> The US sees around 476,000 new Lyme cases every year

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/)

---

### ğŸ‡ºğŸ‡¸ Argo Biopharma doses first patient in phase 2b trial of BWâ€‘20829

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:20
- **é‡è¦æ€§**: â­â­â­

> siRNA therapeutic progresses in global study for patients with elevated Lp(a)

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/argo-biopharma-doses-first-patient-in-phase-2b-trial-of-bw-20829/)

---

### ğŸ‡ºğŸ‡¸ IBSA UK&I launches Perovial for the treatment of acute Peyronieâ€™s disease

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-03 12:32
- **é‡è¦æ€§**: â­â­

> Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronieâ€™s disease

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ibsa-uki-launches-perovial-for-the-treatment-of-acute-peyronies-disease/)

---

### ğŸ‡ºğŸ‡¸ CERo reports encouraging early data from phase 1 trial of CERâ€‘1236

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:59
- **é‡è¦æ€§**: â­

> CERâ€‘T therapy shows initial safety signals and prompts protocol expansion

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/cero-reports-encouraging-early-data-from-phase-1-trial-of-cer-1236/)

---

### ğŸ‡ºğŸ‡¸ ENA Respiratory begins dosing in phase 2 study of INNAâ€‘051 nasal spray

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:44
- **é‡è¦æ€§**: â­

> Trial to assess whether onceâ€‘weekly treatment can reduce symptomatic viral respiratory infections

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ena-respiratory-begins-dosing-in-phase-2-study-of-inna-051-nasal-spray/)

---

### ğŸ‡ºğŸ‡¸ Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-03 12:43

> The company will initially develop a vaccine to tackle colorectal and pancreatic cancers

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/kahimmune-therapeutics-enters-licensing-agreement-with-gustave-roussy-and-satt-paris-saclay/)

---

### ğŸ‡ºğŸ‡¸ ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:08

> Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/)

---

### ğŸ‡ºğŸ‡¸ Akari files new patent and advances second ADC targeting CEACAM5

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:15

> Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/akari-files-new-patent-and-advances-second-adc-targeting-ceacam5/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ FDA Rare Disease Innovation Hub

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 22:19
- **é‡è¦æ€§**: â­â­â­

> FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER with the goal of ultimately improving outcomes for patients.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/fda-rare-disease-innovation-hub)

---

### ğŸ‡ºğŸ‡¸ Summary Metrics of Drug Development Tool Qualification Projects Submitted to FDA

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:33
- **é‡è¦æ€§**: â­â­â­

> This Table provides the current number of active CDER Drug Development Tool (DDT) Qualification projects overall and by Program (DDT- Animal Model Qualification Program, DDT- Biomarker Qualification Program, DDT- Clinical Outcomes Assessment [COA] Qualification Program). Numbers are also provided by

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/summary-metrics-drug-development-tool-qualification-projects-submitted-fda)

---

### ğŸ‡ºğŸ‡¸ CPG Sec. 130.300 FDA Access to Results of Quality Assurance Program Audits and Inspections

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 14:22
- **é‡è¦æ€§**: â­â­

> ORA and CDER agree to replace and/or withdraw CPGs in favor of using guidance or procedural documents, as appropriate per GGP regulations.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-130300-fda-access-results-quality-assurance-program-audits-and-inspections)

---

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 13:09
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:30
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Prescription Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:47
- **é‡è¦æ€§**: â­â­

> The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 20:59

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ National Drug Code Directory

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 20:29

> National Drug Code Directory

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 19:17

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ PDUFA and BsUFA Quarterly Hiring Updates

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 15:06

> PDUFA and BsUFA Quarterly Hiring Updates

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-and-bsufa-quarterly-hiring-updates)

---

### ğŸ‡ºğŸ‡¸ Cohance Lifesciences Limited - 718812 - 01/30/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 14:20

> CGMP/Finished Pharmaceuticals/Adulterated

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cohance-lifesciences-limited-718812-01302026)

---

### ğŸ‡ºğŸ‡¸ HTO Nevada, Inc. dba Kirkman - 719074 - 01/27/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 14:20

> CGMP/Finished Pharmaceuticals/Adulterated

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hto-nevada-inc-dba-kirkman-719074-01272026)

---

### ğŸ‡ºğŸ‡¸ Executive Order 14017 on Americaâ€™s Supply Chains

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-03 13:44

> Updates on recommendations to help shore up the U.S. pharmaceutical supply chain, as directed by Executive Order 14017 on Americaâ€™s Supply Chains

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/reports/executive-order-14017-americas-supply-chains)

---

### ğŸ‡ºğŸ‡¸ Pain and Arthritis Products Containing Hidden Ingredients

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:24

> Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/medication-health-fraud-notifications/pain-and-arthritis-products-containing-hidden-ingredients)

---

### ğŸ‡ºğŸ‡¸ Umary contains hidden drug ingredients

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:23

> The Food and Drug Administration is advising consumers not to purchase or use Umary, a product promoted and sold for pain on various websites, including https://www.solovital.com and possibly in some retail stores.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/medication-health-fraud-notifications/umary-contains-hidden-drug-ingredients)

---

### ğŸ‡ºğŸ‡¸ Electronic Registration and Listing Compliance Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:20

> Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/electronic-registration-and-listing-compliance-program)

---

### ğŸ‡ºğŸ‡¸ Human Drug Compounding

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 21:17

> Compounded drugs can serve an important medical need for certain patients, they also present a risk to patients.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding)

---

### ğŸ‡ºğŸ‡¸ Eurosirel S.P.A - 690733 - 01/26/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:20

> CGMP/Finished Pharmaceuticals/Adulterated

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurosirel-spa-690733-01262026)

---

### ğŸ‡ºğŸ‡¸ Eurosirel S.P.A - 690733 - 11/20/2024

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 19:18

> CGMP/Finished Pharmaceuticals/Adulterated

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurosirel-spa-690733-11202024)

---

### ğŸ‡ºğŸ‡¸ RDEA Pilot Program Disclosure Agreement | Rare Disease Endpoint Advancement Pilot Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-02 17:40

> Disclosure Agreement | Rare Disease Endpoint Advancement Pilot Program

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/rdea-pilot-program-disclosure-agreement-rare-disease-endpoint-advancement-pilot-program)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-02-04 04:10:54*